FDA Grants Rare Pediatric Disease Designation to NV-387 for Measles Treatment

The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Drug (RPDD) Designation to NanoViricides' clinical-stage antiviral drug NV-387 for the treatment of measles. This designation makes NV-387 eligible for a Priority Review Voucher upon successful marketing application, providing incentives such as tax credits for clinical trials, exemption from certain user fees, and potential seven years of market exclusivity after approval.